{"gene":"ICAM1","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1990,"finding":"ICAM-1 (CD54) functions as a counter-receptor for Mac-1 (CD11b/CD18) in addition to LFA-1. Purified Mac-1 and ICAM-1 bind each other in reciprocal cell binding assays using transfected cell lines and immunoaffinity-purified proteins; this interaction mediates adhesion between stimulated neutrophils and stimulated endothelial cells.","method":"Reciprocal cell binding assays with purified proteins, transfected COS and L cells expressing Mac-1 or ICAM-1, antibody blocking, two-color fluorescence conjugate assays","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reciprocal binding with purified proteins and transfected cells, multiple orthogonal assays (binding, blocking, conjugate), replicated across cell systems","pmids":["1980124"],"is_preprint":false},{"year":1991,"finding":"CD43 (sialophorin/leukosialin) binds ICAM-1 (CD54). Daudi cells bind specifically to purified immobilized CD43, and ICAM-1 was identified as a ligand for CD43 on Daudi cells.","method":"Purified immobilized CD43 binding assay, identification of ICAM-1 as the Daudi cell surface ligand","journal":"Nature","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding with purified CD43, single lab, identification of ICAM-1 as counterligand","pmids":["1683685"],"is_preprint":false},{"year":2003,"finding":"Clustering of endothelial ICAM-1 triggers a novel clathrin- and caveolin-independent endocytic pathway that requires dynamin-2, actin rearrangements, Src kinase, and Rho kinase (ROCK), and stimulates formation of actin stress fibers. Internalization requires multimeric (not monomeric) antibody conjugates.","method":"Uptake of anti-ICAM-1 conjugates by endothelial cells; dominant-negative dynamin-2 constructs; pharmacological inhibitors of clathrin, caveolae, macropinocytosis, Src, and ROCK; colocalization studies; actin staining in HUVEC","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal inhibitors, dominant-negative constructs, colocalization, single rigorous study with multiple mechanistic layers","pmids":["12640043"],"is_preprint":false},{"year":2003,"finding":"p53 activates ICAM-1 transcription via two functional p53-responsive elements located in the introns of the ICAM-1 gene, in an NF-κB-independent manner. DNA damage-induced ICAM-1 expression is abolished by the p53 inhibitor pifithrin-alpha and abrogated in p53-deficient cell lines.","method":"p53 inhibitor (pifithrin-alpha), p53-deficient cell lines, mapping of p53-responsive elements in ICAM-1 introns, reporter assays, NF-κB inhibition experiments","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — functional p53 element mapping in ICAM-1 gene, multiple complementary genetic and pharmacological approaches, single lab","pmids":["12660163"],"is_preprint":false},{"year":2000,"finding":"Fibrinogen (Fg) binding to ICAM-1 mediates endothelial cell survival through an anti-apoptotic mechanism. Fg:ICAM-1 ligation induces hyperphosphorylation of ERK-1/2 (8-10 fold) in a cytoskeleton-dependent manner, activating the MAP kinase pathway and upregulating survival factor A1; blocking with ICAM-1(8-22) peptide or dominant-negative ERK-1/2 causes apoptosis.","method":"Annexin V binding apoptosis assay, ERK-1/2 phosphorylation assays, recognition peptides (Fg-gamma-(117-133) and ICAM-1(8-22)), MEK-1 inhibitor (PD 98059), cytoskeleton disruption (cytochalasin B, nocodazole), dominant-negative ERK-1/2 transfection","journal":"European journal of biochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (peptide blocking, dominant-negative, kinase inhibitor, apoptosis assay), single lab","pmids":["10903502"],"is_preprint":false},{"year":2000,"finding":"ICAM-1 expression by vascular smooth muscle cells (SMC) is phenotype-dependent: freshly isolated SMC with high myofilament content express little ICAM-1 (non-inducible by IL-1β), whereas phenotypically modulated SMC with low myofilament content constitutively express ICAM-1 and upregulate it further with IL-1β. Signaling involves adenylyl cyclase but not protein kinase C or NF-κB.","method":"Immunofluorescence staining, flow cytometry, pharmacological inhibitors of PKC (chelerythrine), PTK (genistein), NF-κB (PDTC), and adenylyl cyclase (forskolin) in primary rat aortic SMC","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — phenotype-dependent expression with multiple pharmacological probes, single lab","pmids":["10704620"],"is_preprint":false},{"year":1992,"finding":"Protein kinase C activation (by PMA) induces ICAM-1 expression through a staurosporine-sensitive pathway, whereas IL-1β, TNF-α, and LPS induce ICAM-1 via distinct kinase pathway(s) insensitive to staurosporine. Ionomycin acts synergistically with PMA but not with cytokines or LPS in upregulating ICAM-1.","method":"Protein kinase inhibitors (H-7, HA1004, staurosporine), ionomycin treatment, ELISA and immunoprecipitation of biosynthetically labeled ICAM-1 in HUVEC","journal":"The American journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — discriminatory pharmacological dissection with multiple inhibitors and activators, single lab","pmids":["1347198"],"is_preprint":false},{"year":2017,"finding":"Endothelial ICAM-1 engagement activates ERK, p38, and JNK MAPKs; JNK (and to a lesser degree p38) is the principal MAPK mediating lymphocyte diapedesis across both cerebral and dermal microvascular endothelial cells, whereas ERK is additionally required for TEM across dermal MVECs. JNK drives ICAM-1-induced F-actin rearrangements and phosphorylation of paxillin, which associates with VE-cadherin and promotes its internalization, facilitating lymphocyte TEM. ERK, p38, and JNK also regulate ICAM-1-dependent inflammatory gene expression (TNF-α, CXCL8, CCL3, CCL4, VCAM-1, COX-2).","method":"ICAM-1 engagement by lymphocyte adhesion and antibody clustering; MAPK inhibitors; F-actin staining; paxillin phosphorylation/co-immunoprecipitation with VE-cadherin; VE-cadherin internalization assays; CD4+ lymphocyte TEM assays across cerebral and dermal MVECs","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (kinase inhibitors, co-IP, internalization, actin staining, functional TEM assay), single lab, two cell types","pmids":["28373581"],"is_preprint":false},{"year":1995,"finding":"Co-ligation of ICAM-1 (CD54) with membrane IgM on B cells inhibits BCR-induced intracellular Ca2+ mobilization (both from intracellular stores and extracellular influx), demonstrating that ICAM-1 is coupled to intracellular signaling pathways and can negatively modulate B cell receptor signaling.","method":"Intracellular Ca2+ measurement in Burkitt lymphoma B cells (MTLM4); co-ligation of mIgM and CD54 with limiting anti-IgM concentrations; multiple anti-CD54 mAb tested; Ca2+ measurements in presence and absence of extracellular Ca2+","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — functional Ca2+ signaling assay, multiple antibodies tested, single lab","pmids":["7843226"],"is_preprint":false},{"year":1994,"finding":"ICAM-1 (CD54) on target cells provides costimulation for NK cell-mediated cytotoxicity via LFA-1/MAC-1 interactions. In a three-cell experimental system, ICAM-1-transfected cells (but not LFA-3-transfected cells) significantly enhanced NK cell lysis of K562 targets and anti-CD16-coated targets, acting through remote signaling rather than direct adhesion to target.","method":"Three-cell experimental system with NK cells, 51Cr-labeled target cells, and ICAM-1-transfected or LFA-3-transfected murine cells as costimulators; cytotoxicity assays","journal":"Cellular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — transfected cell system with functional NK cytotoxicity readout, single lab","pmids":["7518755"],"is_preprint":false},{"year":2005,"finding":"ICAM-1 downregulation suppresses human breast cancer cell invasion through Matrigel without affecting proliferation or migration. Anti-ICAM-1 antibody blocks invasion of MDA-MB-435 cells dose-dependently, establishing a causal role for ICAM-1 in cancer cell invasion.","method":"ICAM-1 siRNA knockdown, anti-ICAM-1 antibody blocking, Matrigel invasion assay, cell proliferation assay in human breast cancer cell lines","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal loss-of-function approaches (siRNA and blocking antibody) with defined invasion phenotype, single lab","pmids":["15774488"],"is_preprint":false},{"year":2021,"finding":"Cryo-EM structure of rhinovirus 14 complexed with ICAM-1 at 2.4 Å resolution shows that ICAM-1 binding induces conformational changes in the rhinovirus 14 capsid, including translocation of VP4 C-termini, blocking of RNA-VP2 interactions, exposure of positively charged residues, and redistribution of the viral genome — priming the virus for activation and genome release at acidic pH.","method":"Cryo-EM structure determination of rhinovirus 14 alone (2.6 Å) and in complex with ICAM-1 (2.4 Å); structural analysis of conformational changes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution cryo-EM structure with mechanistic interpretation of conformational changes, rigorous structural study","pmids":["33947819"],"is_preprint":false},{"year":2003,"finding":"Gingipains (cysteine proteinases) from Porphyromonas gingivalis directly cleave ICAM-1 on human oral epithelial cell surfaces in a time- and dose-dependent manner, disrupting ICAM-1-dependent PMN adhesion to epithelial cells, representing a mechanism of immune evasion.","method":"Flow cytometry and Western blotting of ICAM-1 on KB and HSC-2 cells; treatment with purified gingipain forms; fixed-cell proteolysis assay; PMN adhesion assay","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct proteolysis on fixed cells confirmed, multiple gingipain forms tested, functional adhesion assay, single lab","pmids":["14514759"],"is_preprint":false},{"year":2017,"finding":"Aldosterone promotes endothelial ICAM-1 transcription through the mineralocorticoid receptor (MR). Luciferase reporter assays with deletion constructs of the ICAM-1 promoter in HUVECs identified a region containing an MR-responsive element (MRE) required for MR-dependent ICAM-1 transcriptional regulation. In vivo, ApoE/ICAM-1 double-knockout mice are protected from aldosterone-induced atherosclerotic plaque growth, confirming ICAM-1 as the effector of aldosterone's pro-atherogenic effects.","method":"Luciferase reporter assays with ICAM-1 promoter deletion constructs in HUVECs; ApoE-/-/ICAM-1-/- double-knockout mice; aldosterone-treatment atherosclerosis model","journal":"International journal of cardiology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — promoter deletion/reporter assays define MRE + genetic rescue in double-KO mice, two complementary approaches, single lab","pmids":["28089144"],"is_preprint":false},{"year":2018,"finding":"ICAM-1 is required cell-intrinsically for the development and function of group 2 innate lymphoid cells (ILC2s). ICAM-1-deficient mice have fewer ILC2s in bone marrow and peripheral tissues; CLP transfer and in vitro culture assays confirm cell-intrinsic regulation. ICAM-1 deficiency impairs ILC2 cytokine production in response to IL-33 via ERK signaling-dependent downregulation of GATA3.","method":"ICAM-1-deficient mice; CLP transfer assays; in vitro culture; IL-33 challenge; cytokine measurement; ERK signaling analysis; GATA3 protein quantification","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO + cell-intrinsic transfer assays + defined molecular pathway (ERK/GATA3), single lab with multiple orthogonal approaches","pmids":["30049704"],"is_preprint":false},{"year":2015,"finding":"FOXO1 directly binds the ICAM-1 promoter, stimulates ICAM-1 transcriptional activity, and regulates ICAM-1 expression in dendritic cells (DCs). Transfection of ICAM-1-expressing plasmid into FOXO1-deleted DCs rescues impaired bacterial phagocytosis and chemotaxis, placing ICAM-1 as a key downstream effector of FOXO1 in DC function.","method":"ChIP showing FOXO1 binding to ICAM-1 promoter; FOXO1 promoter-luciferase reporter assays; lineage-specific FOXO1 knockout (CD11c.Cre+FOXO1L/L mice); rescue with ICAM-1-expressing plasmid; phagocytosis, chemotaxis, and DC homing assays","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP + reporter assay + genetic KO + functional rescue, multiple orthogonal methods, single lab","pmids":["25786691"],"is_preprint":false},{"year":2019,"finding":"Musashi-1 (MSI1) promotes ICAM-1 translation in glioblastoma cells. RNA immunoprecipitation assays demonstrate that MSI1 physically interacts with ICAM-1 mRNA, and MSI1 knockdown suppresses ICAM-1 expression, cell motility, and invasion; overexpression of ICAM-1 reverses these effects.","method":"RNA immunoprecipitation (RIP) assay; MSI1 knockdown; ICAM-1 overexpression rescue; cell motility and invasion assays","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RIP demonstrates direct mRNA interaction, rescue experiment confirms ICAM-1 as downstream effector, single lab","pmids":["30959276"],"is_preprint":false},{"year":2017,"finding":"CD54 (ICAM-1) mediates cancer stem cell self-renewal and tumorigenesis in prostate cancer through the p38-Notch1 signaling axis. Silencing CD54 reduces tumorigenesis in vitro and in vivo; dissection of downstream signaling identified p38-Notch1 as the principal pathway.","method":"CD54 silencing (siRNA/shRNA); patient-derived xenograft model; in vitro self-renewal assays; in vivo xenograft; pathway inhibition/dissection for p38-Notch1","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KD with in vivo confirmation and pathway dissection, single lab","pmids":["28042317"],"is_preprint":false},{"year":2021,"finding":"ICAM-1 expression in non-irradiated tumors enhances activation and tumor infiltration of CD8+ T cells, thereby promoting the abscopal effect of radiotherapy. Genetic or pharmacologic upregulation of ICAM-1 markedly increases abscopal responses in animal models.","method":"ICAM-1 knockout; intratumoral injection of recombinant adenovirus encoding ICAM-1; TLR7 agonist nanodrug; PET/optical imaging of ICAM-1 expression; flow cytometry of CD8+ T cells; tumor growth measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacologic gain/loss-of-function in vivo, CD8+ T cell mechanistic readout, single lab","pmids":["33785590"],"is_preprint":false},{"year":2021,"finding":"Macrophage ICAM-1 expression, induced by LPS via TLR4-mediated ROS production, is required for LPS-enhanced macrophage phagocytosis. ICAM-1 neutralizing antibody or ICAM-1 siRNA silencing reduces LPS-induced phagocytosis; TLR4 knockout inhibits cytoplasmic and mitochondrial ROS production, which in turn attenuates ICAM-1 expression.","method":"ICAM-1 neutralizing antibody; ICAM-1 siRNA; TLR4 knockout mice; flow cytometry; confocal microscopy; ROS measurement; phagocytosis assay","journal":"Inflammation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal loss-of-function (antibody + siRNA) + genetic TLR4 KO for upstream pathway, single lab","pmids":["33474594"],"is_preprint":false},{"year":2006,"finding":"In senescent endothelial cells, ICAM-1 transitions from directed to random motion within the membrane. Single particle tracking shows 44% reduced ICAM-1 mobility in late-passage cells after PKC stimulation, partly explained by reduced alpha-actinin linking with ICAM-1 and markedly reduced tyrosine phosphorylation of alpha-actinin (required for ICAM-1 clustering) in senescent cells.","method":"Single particle tracking; PKC activator (PMA); immunoprecipitation of alpha-actinin with ICAM-1; tyrosine phosphorylation assay; early vs. late passage HPAEC comparison","journal":"Mechanisms of ageing and development","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — single particle tracking with co-IP and phosphorylation analysis, single lab","pmids":["16930678"],"is_preprint":false},{"year":2019,"finding":"NANOG directly binds to the region upstream of the ICAM-1 gene, and increased NANOG binding is associated with diminished p300 binding at this region, resulting in decreased ICAM-1 expression. This mechanism enables prostate cancer cells to evade NK cell attack during tumorigenesis.","method":"RNAseq; ChIPseq of NANOG and p300 at the ICAM-1 upstream region; NANOG overexpression; NK cell cytotoxicity assays; xenograft in SCID mice","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIPseq demonstrates direct NANOG binding + p300 displacement at ICAM-1 locus, functional NK assay, single lab","pmids":["31619256"],"is_preprint":false},{"year":2015,"finding":"MicroRNA-222 (miR-222) transported into endothelial cells by endothelial microparticles (EMP) post-transcriptionally downregulates ICAM-1 expression (mRNA and protein), reducing monocyte adhesion in vitro and endothelial ICAM-1 expression in ApoE-/- mice in vivo.","method":"Taqman microRNA array; miR-222 transfer via EMP; ICAM-1 mRNA and protein measurement; monocyte adhesion assay; ApoE-/- mouse in vivo model; miR-222 mimic/inhibitor experiments","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — miRNA array + functional miR transfer + in vitro and in vivo validation, single lab","pmids":["26081516"],"is_preprint":false},{"year":1996,"finding":"CD30L and CD40L (but not 4-1BBL) upregulate ICAM-1 (CD54) surface expression and shedding in Hodgkin and Reed-Sternberg (H-RS) cells via transcriptional gene activation, as demonstrated at both mRNA and protein levels. Enhanced surface ICAM-1 is accompanied by increased shedding of an 82 kDa soluble CD54 form.","method":"CD30L and CD40L stimulation of H-RS cell lines; ICAM-1 mRNA and protein measurement; soluble CD54 measurement in culture supernatants","journal":"Leukemia","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cytokine stimulation assays, mRNA/protein readouts, single lab, no detailed mechanistic dissection","pmids":["8656679"],"is_preprint":false},{"year":2000,"finding":"90% of human rhinovirus (HRV) serotypes use ICAM-1 as a cell-entry receptor. ICAM-1 positions the virus near the membrane and triggers a conformational change in the viral capsid leading to genome delivery across the lipid bilayer. Structural models from crystal structures of HRV and ICAM-1 fragments combined with EM reconstructions of complexes define receptor recognition and uncoating mechanism.","method":"Combined crystal structures of HRVs and ICAM-1 fragments with electron microscopy reconstructions of rhinovirus-ICAM-1 complexes","journal":"Pharmaceutica acta Helvetiae","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural analysis (crystal + EM), but review/summary paper compiling prior structural work; no new experiment described in abstract","pmids":["10812972"],"is_preprint":false},{"year":2015,"finding":"IL-33 induces ICAM-1 expression in murine mast cells via the NF-κB pathway, and this ICAM-1 upregulation increases mast cell adhesion to LFA-1-coated plates. Pre-treatment with an NF-κB inhibitor dramatically reduces IL-33-induced ICAM-1 expression.","method":"IL-33 stimulation of bone marrow-derived mast cells (BMMCs); NF-κB inhibitor; ICAM-1 siRNA transfection; cell adhesion assay to LFA-1-coated plate; in vivo IL-33 intradermal injection in mice with ICAM-1 immunohistochemistry","journal":"Allergology international","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — NF-κB inhibitor + siRNA + functional adhesion assay + in vivo confirmation, single lab","pmids":["26666474"],"is_preprint":false}],"current_model":"ICAM-1 (CD54) is a transmembrane immunoglobulin superfamily glycoprotein that functions as an adhesion and signaling molecule: it serves as a counter-receptor for leukocyte integrins LFA-1 and Mac-1 (mediating leukocyte firm arrest and transendothelial migration), acts as the entry receptor for ~90% of human rhinovirus serotypes (binding induces conformational changes in the viral capsid that prime genome release), engages fibrinogen to activate ERK-dependent endothelial cell survival signaling, triggers a novel dynamin/actin/ROCK-dependent endocytic pathway upon clustering, activates ERK/p38/JNK MAPKs upon leukocyte engagement to direct both lymphocyte diapedesis (via JNK-paxillin-VE-cadherin) and inflammatory gene expression, is transcriptionally regulated by NF-κB, p53 (via intronic response elements), mineralocorticoid receptor, and FOXO1, and post-transcriptionally regulated by miR-222; ICAM-1 also controls ILC2 development and function via ERK/GATA3 signaling and mediates cancer cell invasion, stem cell self-renewal (via p38-Notch1), and NK cell evasion (through NANOG-mediated transcriptional repression)."},"narrative":{"mechanistic_narrative":"ICAM-1 (CD54) is a cell-surface adhesion and signaling receptor that orchestrates leukocyte trafficking, immune cell function, and pathogen entry [PMID:1980124, PMID:28373581]. It serves as a counter-receptor for the leukocyte integrins LFA-1 and Mac-1 (CD11b/CD18), mediating firm adhesion between stimulated neutrophils and endothelial cells [PMID:1980124], and also engages CD43 as an additional counter-ligand [PMID:1683685]. Beyond passive adhesion, ICAM-1 is a bidirectional signaling molecule: endothelial engagement activates ERK, p38, and JNK MAPKs, with JNK driving F-actin rearrangement and paxillin phosphorylation that promotes VE-cadherin internalization to permit lymphocyte transendothelial migration, while the same MAPKs drive inflammatory gene expression [PMID:28373581]. Clustering of endothelial ICAM-1 triggers a distinct clathrin- and caveolin-independent endocytic route dependent on dynamin-2, actin, Src, and ROCK [PMID:12640043], and its membrane mobility and clustering are governed by alpha-actinin linkage and tyrosine phosphorylation [PMID:16930678]. ICAM-1 also transduces survival signals: fibrinogen binding induces cytoskeleton-dependent ERK-1/2 hyperphosphorylation and anti-apoptotic A1 upregulation in endothelium [PMID:10903502]. As an entry receptor for ~90% of human rhinovirus serotypes, ICAM-1 binding induces capsid conformational changes—VP4 C-terminus translocation, disruption of RNA-VP2 contacts, and genome redistribution—that prime the virus for uncoating and genome release [PMID:10812972, PMID:33947819]. ICAM-1 transcription is controlled by multiple inputs including p53 via intronic response elements [PMID:12660163], the mineralocorticoid receptor [PMID:28089144], FOXO1 in dendritic cells [PMID:25786691], and NF-κB [PMID:26666474], and is repressed by NANOG via p300 displacement [PMID:31619256] and post-transcriptionally by miR-222 [PMID:26081516] and stabilized translationally by Musashi-1 [PMID:30959276]. Functionally, ICAM-1 is required cell-intrinsically for ILC2 development through ERK/GATA3 signaling [PMID:30049704], supports macrophage phagocytosis downstream of TLR4/ROS [PMID:33474594], and contributes to cancer cell invasion and stem cell self-renewal via p38-Notch1 [PMID:15774488, PMID:28042317].","teleology":[{"year":1990,"claim":"Established that ICAM-1 is not solely an LFA-1 ligand but also a counter-receptor for the integrin Mac-1, broadening its role in neutrophil-endothelial adhesion.","evidence":"Reciprocal binding with purified Mac-1 and ICAM-1, transfected COS/L cells, antibody blocking, and conjugate assays","pmids":["1980124"],"confidence":"High","gaps":["Affinity and stoichiometry of the Mac-1 interaction not quantified","Downstream signaling from Mac-1 engagement not addressed"]},{"year":1991,"claim":"Identified CD43 as an additional ICAM-1 counter-ligand, expanding the repertoire of ICAM-1 adhesion partners beyond integrins.","evidence":"Purified immobilized CD43 binding assay with Daudi cells","pmids":["1683685"],"confidence":"Medium","gaps":["Physiological context of CD43-ICAM-1 binding unclear","No reciprocal validation or structural mapping"]},{"year":1992,"claim":"Distinguished signaling routes inducing ICAM-1, showing PKC-dependent induction is mechanistically separate from cytokine/LPS-driven induction.","evidence":"Kinase inhibitors and PMA/ionomycin treatment with ELISA/IP in HUVEC","pmids":["1347198"],"confidence":"Medium","gaps":["Specific cytokine-induced kinases not identified","Transcription factors mediating each route undefined"]},{"year":1994,"claim":"Showed ICAM-1 on target cells costimulates NK cytotoxicity through remote signaling rather than direct target adhesion, implicating it in NK effector function.","evidence":"Three-cell cytotoxicity system with ICAM-1- vs LFA-3-transfected costimulators","pmids":["7518755"],"confidence":"Medium","gaps":["Mechanism of 'remote' signaling not defined","Receptor on NK cells transmitting the signal unclear"]},{"year":1995,"claim":"Demonstrated ICAM-1 is coupled to intracellular signaling and can negatively modulate BCR-induced calcium flux in B cells.","evidence":"Intracellular Ca2+ measurement with mIgM/CD54 co-ligation in Burkitt lymphoma cells","pmids":["7843226"],"confidence":"Medium","gaps":["Signaling intermediates linking ICAM-1 to Ca2+ suppression unknown","Physiological relevance to B cell biology not established"]},{"year":2000,"claim":"Revealed ICAM-1 as a survival receptor, with fibrinogen ligation activating ERK to suppress endothelial apoptosis.","evidence":"Apoptosis assays, ERK phosphorylation, recognition peptides, dominant-negative ERK, MEK inhibitor in endothelial cells","pmids":["10903502"],"confidence":"High","gaps":["Cytoplasmic adaptor coupling ICAM-1 to ERK not identified","In vivo relevance of fibrinogen-ICAM-1 survival signaling untested"]},{"year":2000,"claim":"Showed ICAM-1 expression in vascular smooth muscle is phenotype-dependent and uses an adenylyl cyclase route distinct from NF-κB/PKC.","evidence":"Immunofluorescence, flow cytometry, pharmacological inhibitors in primary rat aortic SMC","pmids":["10704620"],"confidence":"Medium","gaps":["Transcription factors downstream of adenylyl cyclase not identified","Single-species (rat) primary cells"]},{"year":2003,"claim":"Defined p53 as a direct transcriptional activator of ICAM-1 via intronic response elements, linking DNA damage to adhesion molecule expression independent of NF-κB.","evidence":"p53 inhibitor, p53-null cell lines, intronic element mapping, reporter assays","pmids":["12660163"],"confidence":"High","gaps":["Physiological setting of p53-driven ICAM-1 induction unclear","Cofactors at intronic elements not characterized"]},{"year":2003,"claim":"Discovered that ICAM-1 clustering activates a novel dynamin/actin/Src/ROCK-dependent endocytic pathway, defining how engaged ICAM-1 is internalized.","evidence":"Anti-ICAM-1 conjugate uptake, dominant-negative dynamin-2, pathway inhibitors, colocalization, actin staining in HUVEC","pmids":["12640043"],"confidence":"High","gaps":["Cargo and fate of internalized ICAM-1 not fully traced","Link between this pathway and leukocyte transmigration not established"]},{"year":2003,"claim":"Identified bacterial proteolysis of ICAM-1 by P. gingivalis gingipains as an immune evasion mechanism that disrupts neutrophil adhesion.","evidence":"Flow cytometry/Western of cleaved ICAM-1, fixed-cell proteolysis, PMN adhesion assay","pmids":["14514759"],"confidence":"Medium","gaps":["Cleavage sites not mapped","In vivo contribution to periodontal immune evasion untested"]},{"year":2005,"claim":"Established a causal role for ICAM-1 in cancer cell invasion independent of proliferation or migration.","evidence":"siRNA knockdown and blocking antibody in Matrigel invasion assay in breast cancer cells","pmids":["15774488"],"confidence":"Medium","gaps":["Molecular mediators of invasion downstream of ICAM-1 not identified","Limited to single cancer cell line"]},{"year":2006,"claim":"Linked ICAM-1 membrane mobility and clustering to alpha-actinin cytoskeletal coupling, which is lost in senescent endothelium.","evidence":"Single particle tracking, alpha-actinin co-IP, tyrosine phosphorylation assay in early vs late passage endothelial cells","pmids":["16930678"],"confidence":"Medium","gaps":["Kinase phosphorylating alpha-actinin not identified","Functional consequence for leukocyte capture in senescence not measured"]},{"year":2015,"claim":"Identified FOXO1 as a direct ICAM-1 promoter activator and showed ICAM-1 is the key effector of FOXO1 in dendritic cell phagocytosis and chemotaxis.","evidence":"ChIP, reporter assays, lineage-specific FOXO1 knockout, ICAM-1 rescue, DC functional assays","pmids":["25786691"],"confidence":"High","gaps":["How ICAM-1 promotes DC chemotaxis mechanistically unclear","Other FOXO1 targets contributing to phenotype not excluded"]},{"year":2015,"claim":"Showed IL-33 induces mast cell ICAM-1 via NF-κB to promote LFA-1-dependent adhesion, integrating ICAM-1 into allergic effector responses.","evidence":"IL-33 stimulation, NF-κB inhibitor, ICAM-1 siRNA, adhesion assay, in vivo IL-33 injection","pmids":["26666474"],"confidence":"Medium","gaps":["Specific NF-κB subunits at the ICAM-1 promoter not defined","Downstream signaling from mast cell ICAM-1 not addressed"]},{"year":2015,"claim":"Established post-transcriptional control of ICAM-1 by microparticle-delivered miR-222, modulating endothelial monocyte adhesion in atherosclerosis.","evidence":"miRNA array, EMP-mediated miR-222 transfer, mRNA/protein readouts, adhesion assay, ApoE-/- mice","pmids":["26081516"],"confidence":"Medium","gaps":["Direct ICAM-1 3'UTR target site not mapped","Other miR-222 targets contributing in vivo not excluded"]},{"year":2017,"claim":"Demonstrated that endothelial ICAM-1 engagement signals through ERK/p38/JNK MAPKs, with JNK driving paxillin-dependent VE-cadherin internalization to enable lymphocyte transendothelial migration and inflammatory gene expression.","evidence":"Antibody clustering/adhesion, MAPK inhibitors, co-IP of paxillin with VE-cadherin, internalization and TEM assays across two endothelial types","pmids":["28373581"],"confidence":"High","gaps":["Direct kinase substrate linking ICAM-1 to JNK not defined","How JNK selectively phosphorylates paxillin not resolved"]},{"year":2017,"claim":"Implicated ICAM-1 in cancer stem cell self-renewal and tumorigenesis through the p38-Notch1 axis in prostate cancer.","evidence":"CD54 silencing, PDX and xenograft models, self-renewal assays, p38-Notch1 pathway dissection","pmids":["28042317"],"confidence":"Medium","gaps":["How ICAM-1 activates p38 in cancer stem cells unclear","Receptor partner triggering this axis not identified"]},{"year":2017,"claim":"Identified the mineralocorticoid receptor as a direct transcriptional driver of endothelial ICAM-1 and showed ICAM-1 is the effector of aldosterone's pro-atherogenic effects.","evidence":"Promoter deletion/reporter assays defining an MRE, ApoE-/-/ICAM-1-/- double-knockout aldosterone atherosclerosis model","pmids":["28089144"],"confidence":"High","gaps":["MR cofactors at the ICAM-1 promoter not characterized","Cell types beyond endothelium not examined"]},{"year":2018,"claim":"Revealed a cell-intrinsic requirement for ICAM-1 in ILC2 development and IL-33-driven cytokine production via ERK-dependent maintenance of GATA3.","evidence":"ICAM-1-deficient mice, CLP transfer, in vitro culture, IL-33 challenge, ERK/GATA3 analysis","pmids":["30049704"],"confidence":"High","gaps":["How ICAM-1 cell-intrinsically activates ERK in ILC2s unknown","Ligand engaging ICAM-1 in this context not identified"]},{"year":2019,"claim":"Showed Musashi-1 binds ICAM-1 mRNA and promotes its translation to drive glioblastoma motility and invasion, defining a translational layer of ICAM-1 control.","evidence":"RNA immunoprecipitation, MSI1 knockdown, ICAM-1 overexpression rescue, motility/invasion assays","pmids":["30959276"],"confidence":"Medium","gaps":["MSI1 binding site on ICAM-1 mRNA not mapped","Whether translation enhancement requires other RBPs unknown"]},{"year":2019,"claim":"Established that NANOG directly represses ICAM-1 by displacing p300 at the locus, enabling prostate cancer NK cell immune evasion.","evidence":"ChIPseq of NANOG and p300, NANOG overexpression, NK cytotoxicity, SCID xenograft","pmids":["31619256"],"confidence":"Medium","gaps":["Mechanism of p300 displacement by NANOG unclear","Other repressive cofactors not characterized"]},{"year":2021,"claim":"Provided high-resolution structural mechanism showing ICAM-1 binding to rhinovirus 14 induces capsid conformational changes that prime genome release.","evidence":"Cryo-EM of rhinovirus 14 alone and complexed with ICAM-1 at 2.4 Å","pmids":["33947819"],"confidence":"High","gaps":["Sequence of events between binding and uncoating at acidic pH not temporally resolved","Membrane penetration step not visualized"]},{"year":2021,"claim":"Showed macrophage ICAM-1, induced via TLR4-mediated ROS, is required for LPS-enhanced phagocytosis, linking innate sensing to ICAM-1 effector function.","evidence":"ICAM-1 neutralizing antibody, siRNA, TLR4-KO mice, ROS measurement, phagocytosis assay","pmids":["33474594"],"confidence":"Medium","gaps":["How ICAM-1 promotes phagocytic uptake mechanistically unclear","Phagocytic ligand engaging ICAM-1 not identified"]},{"year":2021,"claim":"Demonstrated that ICAM-1 in non-irradiated tumors enhances CD8+ T cell activation and infiltration to promote the abscopal effect of radiotherapy.","evidence":"ICAM-1 knockout, adenoviral ICAM-1, TLR7 agonist nanodrug, imaging, CD8+ T cell flow cytometry, tumor growth","pmids":["33785590"],"confidence":"Medium","gaps":["Mechanism by which tumor ICAM-1 enhances CD8+ T cell activation unresolved","Translatability to clinical radiotherapy untested"]},{"year":null,"claim":"How the ICAM-1 cytoplasmic tail mechanistically couples surface engagement to the diverse MAPK, survival, and lineage-specific transcriptional programs across cell types remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model of cytoplasmic adaptor recruitment","Cell-type specificity of ICAM-1 outside-in signaling not explained","Structural basis of integrin (LFA-1/Mac-1) engagement not resolved in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[24,11]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[7,4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,2,20]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,7,14]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,4]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[24,11]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,13,15]}],"complexes":[],"partners":["ITGAM","ITGB2","ITGAL","CD43","FGA","VE-CADHERIN","ACTN1","MSI1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P05362","full_name":"Intercellular adhesion molecule 1","aliases":["Major group rhinovirus receptor"],"length_aa":532,"mass_kda":57.8,"function":"Cell adhesion molecule that functions as a receptor ligand of the signaling receptor ITGAL:ITGB2/LFA-1 (lymphocyte-function associated (LFA) molecule 1) ensuring leukocyte cell-cell adhesion, by providing a calibrated system to namely adjust T-cell killing to the antigen stimulation strength (PubMed:3086451, PubMed:3340213, PubMed:38195629). Also functions as a ligand receptor of the signaling receptor ITGAM:ITGB2/MAC-1 ensuring adhesion between stimulated neutrophils and stimulated endothelial cells (PubMed:1980124). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation (PubMed:17875742). Promotes cell aggregation in epithelial cells through interaction with MUC1 (PubMed:11173916) (Microbial infection) Acts as a receptor for major receptor group rhinovirus A-B capsid proteins (Microbial infection) Acts as a receptor for Coxsackievirus A21 capsid proteins (Microbial infection) Upon Kaposi's sarcoma-associated herpesvirus/HHV-8 infection, is degraded by viral E3 ubiquitin ligase MIR2, presumably to prevent lysis of infected cells by cytotoxic T-lymphocytes and NK cell","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P05362/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ICAM1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ICAM1","total_profiled":1310},"omim":[{"mim_id":"620376","title":"AUTOINFLAMMATORY DISEASE, SYSTEMIC, WITH VASCULITIS; SAIDV","url":"https://www.omim.org/entry/620376"},{"mim_id":"617082","title":"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iaa; CDG1AA","url":"https://www.omim.org/entry/617082"},{"mim_id":"616761","title":"SUSHI DOMAIN-CONTAINING PROTEIN 6; SUSD6","url":"https://www.omim.org/entry/616761"},{"mim_id":"615977","title":"MICRO RNA 339; MIR339","url":"https://www.omim.org/entry/615977"},{"mim_id":"614138","title":"TRAFFICKING PROTEIN PARTICLE COMPLEX, SUBUNIT 11; TRAPPC11","url":"https://www.omim.org/entry/614138"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lung","ntpm":233.5},{"tissue":"urinary bladder","ntpm":200.0}],"url":"https://www.proteinatlas.org/search/ICAM1"},"hgnc":{"alias_symbol":["BB2","CD54"],"prev_symbol":[]},"alphafold":{"accession":"P05362","domains":[{"cath_id":"2.60.40.10","chopping":"28-109","consensus_level":"high","plddt":91.441,"start":28,"end":109},{"cath_id":"2.60.40.10","chopping":"114-211","consensus_level":"high","plddt":95.8334,"start":114,"end":211},{"cath_id":"2.60.40.10","chopping":"219-306","consensus_level":"high","plddt":95.1957,"start":219,"end":306},{"cath_id":"2.60.40.10","chopping":"313-393","consensus_level":"high","plddt":91.1678,"start":313,"end":393},{"cath_id":"2.60.40.10","chopping":"398-476","consensus_level":"high","plddt":92.5801,"start":398,"end":476}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P05362","model_url":"https://alphafold.ebi.ac.uk/files/AF-P05362-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P05362-F1-predicted_aligned_error_v6.png","plddt_mean":88.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ICAM1","jax_strain_url":"https://www.jax.org/strain/search?query=ICAM1"},"sequence":{"accession":"P05362","fasta_url":"https://rest.uniprot.org/uniprotkb/P05362.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P05362/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P05362"}},"corpus_meta":[{"pmid":"1980124","id":"PMC_1980124","title":"ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18).","date":"1990","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1980124","citation_count":898,"is_preprint":false},{"pmid":"19307690","id":"PMC_19307690","title":"ICAM-1 signaling in endothelial cells.","date":"2009","source":"Pharmacological reports : PR","url":"https://pubmed.ncbi.nlm.nih.gov/19307690","citation_count":553,"is_preprint":false},{"pmid":"37442359","id":"PMC_37442359","title":"ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders.","date":"2023","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37442359","citation_count":297,"is_preprint":false},{"pmid":"1683685","id":"PMC_1683685","title":"CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1.","date":"1991","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/1683685","citation_count":270,"is_preprint":false},{"pmid":"12640043","id":"PMC_12640043","title":"A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1.","date":"2003","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/12640043","citation_count":254,"is_preprint":false},{"pmid":"7806065","id":"PMC_7806065","title":"Expression of interleukin 8 and CD54 by human gastric epithelium after Helicobacter pylori infection in vitro.","date":"1995","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/7806065","citation_count":249,"is_preprint":false},{"pmid":"15774488","id":"PMC_15774488","title":"Role of ICAM1 in invasion of human breast cancer cells.","date":"2005","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/15774488","citation_count":230,"is_preprint":false},{"pmid":"7543921","id":"PMC_7543921","title":"Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation.","date":"1995","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/7543921","citation_count":201,"is_preprint":false},{"pmid":"15886114","id":"PMC_15886114","title":"ICAM-1 co-stimulates target cells to facilitate antigen presentation.","date":"2005","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15886114","citation_count":149,"is_preprint":false},{"pmid":"2571505","id":"PMC_2571505","title":"MALA-2, mouse homologue of human adhesion molecule ICAM-1 (CD54).","date":"1989","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/2571505","citation_count":144,"is_preprint":false},{"pmid":"18808323","id":"PMC_18808323","title":"Hug tightly and say goodbye: role of endothelial ICAM-1 in leukocyte transmigration.","date":"2009","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/18808323","citation_count":135,"is_preprint":false},{"pmid":"24795464","id":"PMC_24795464","title":"ICAM-1: isoforms and phenotypes.","date":"2014","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24795464","citation_count":128,"is_preprint":false},{"pmid":"7525451","id":"PMC_7525451","title":"Polymorphisms and linkage analysis for ICAM-1 and the selectin gene cluster.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7525451","citation_count":122,"is_preprint":false},{"pmid":"18363595","id":"PMC_18363595","title":"Soluble ICAM-1 and VCAM-1 as markers of endothelial activation.","date":"2008","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18363595","citation_count":122,"is_preprint":false},{"pmid":"1673030","id":"PMC_1673030","title":"Interleukin 4 promotes expression of mast cell ICAM-1 antigen.","date":"1991","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/1673030","citation_count":119,"is_preprint":false},{"pmid":"1974471","id":"PMC_1974471","title":"Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders.","date":"1990","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1974471","citation_count":116,"is_preprint":false},{"pmid":"7682455","id":"PMC_7682455","title":"Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas.","date":"1993","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7682455","citation_count":115,"is_preprint":false},{"pmid":"29099772","id":"PMC_29099772","title":"Role of LFA-1 and ICAM-1 in Cancer.","date":"2017","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/29099772","citation_count":113,"is_preprint":false},{"pmid":"26081516","id":"PMC_26081516","title":"Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26081516","citation_count":112,"is_preprint":false},{"pmid":"1376489","id":"PMC_1376489","title":"Expression and regulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human intestinal epithelial cell lines.","date":"1992","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1376489","citation_count":110,"is_preprint":false},{"pmid":"1346541","id":"PMC_1346541","title":"Modulation and function of intercellular adhesion molecule-1 (CD54) on human retinal pigment epithelial cells.","date":"1992","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/1346541","citation_count":107,"is_preprint":false},{"pmid":"1721526","id":"PMC_1721526","title":"Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.","date":"1991","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/1721526","citation_count":99,"is_preprint":false},{"pmid":"8100190","id":"PMC_8100190","title":"Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis.","date":"1993","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/8100190","citation_count":96,"is_preprint":false},{"pmid":"28089144","id":"PMC_28089144","title":"Essential role of ICAM-1 in aldosterone-induced atherosclerosis.","date":"2017","source":"International journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28089144","citation_count":93,"is_preprint":false},{"pmid":"18297282","id":"PMC_18297282","title":"CD54 is a surrogate marker of antigen presenting cell activation.","date":"2008","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/18297282","citation_count":88,"is_preprint":false},{"pmid":"9032180","id":"PMC_9032180","title":"Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum.","date":"1997","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9032180","citation_count":83,"is_preprint":false},{"pmid":"12660163","id":"PMC_12660163","title":"p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner.","date":"2003","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/12660163","citation_count":80,"is_preprint":false},{"pmid":"28943897","id":"PMC_28943897","title":"Role of liver ICAM-1 in metastasis.","date":"2017","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/28943897","citation_count":80,"is_preprint":false},{"pmid":"15724813","id":"PMC_15724813","title":"The role of ICAM-1 in Plasmodium falciparum cytoadherence.","date":"2005","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15724813","citation_count":77,"is_preprint":false},{"pmid":"1671649","id":"PMC_1671649","title":"Expression of intercellular adhesion molecule-1 (CD54) on hematopoietic progenitors.","date":"1991","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/1671649","citation_count":77,"is_preprint":false},{"pmid":"1973649","id":"PMC_1973649","title":"Induction of human thyroid cell ICAM-1 (CD54) antigen expression and ICAM-1-mediated lymphocyte binding.","date":"1990","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1973649","citation_count":73,"is_preprint":false},{"pmid":"30339462","id":"PMC_30339462","title":"The ORMDL3 Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation.","date":"2019","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30339462","citation_count":72,"is_preprint":false},{"pmid":"10367680","id":"PMC_10367680","title":"Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.","date":"1999","source":"Toxicologic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10367680","citation_count":72,"is_preprint":false},{"pmid":"15063588","id":"PMC_15063588","title":"ICAM-1: targeted docking for exogenous as well as endogenous ligands.","date":"2004","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15063588","citation_count":72,"is_preprint":false},{"pmid":"16331675","id":"PMC_16331675","title":"Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16331675","citation_count":69,"is_preprint":false},{"pmid":"28658631","id":"PMC_28658631","title":"PAX7 Targets, CD54, Integrin α9β1, and SDC2, Allow Isolation of Human ESC/iPSC-Derived Myogenic Progenitors.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28658631","citation_count":68,"is_preprint":false},{"pmid":"8683139","id":"PMC_8683139","title":"Heat shock protein 65 induces CD62e, CD106, and CD54 on cultured human endothelial cells and increases their adhesiveness for monocytes and granulocytes.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8683139","citation_count":66,"is_preprint":false},{"pmid":"11051236","id":"PMC_11051236","title":"Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.","date":"2000","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11051236","citation_count":65,"is_preprint":false},{"pmid":"30049704","id":"PMC_30049704","title":"ICAM-1 controls development and function of ILC2.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30049704","citation_count":64,"is_preprint":false},{"pmid":"12691701","id":"PMC_12691701","title":"Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells.","date":"2003","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12691701","citation_count":62,"is_preprint":false},{"pmid":"26256381","id":"PMC_26256381","title":"Rhamnogalacturonan I containing homogalacturonan inhibits colon cancer cell proliferation by decreasing ICAM1 expression.","date":"2015","source":"Carbohydrate polymers","url":"https://pubmed.ncbi.nlm.nih.gov/26256381","citation_count":61,"is_preprint":false},{"pmid":"7518755","id":"PMC_7518755","title":"CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity.","date":"1994","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7518755","citation_count":59,"is_preprint":false},{"pmid":"7516927","id":"PMC_7516927","title":"Regulation of ICAM-1 (CD54) expression in human breast cancer cell lines by interleukin 6 and fibroblast-derived factors.","date":"1994","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7516927","citation_count":59,"is_preprint":false},{"pmid":"1347198","id":"PMC_1347198","title":"Discriminatory effects of protein kinase inhibitors and calcium ionophore on endothelial ICAM-1 induction.","date":"1992","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/1347198","citation_count":58,"is_preprint":false},{"pmid":"22939995","id":"PMC_22939995","title":"IL-6 promotes ICAM-1 expression and cell motility in human osteosarcoma.","date":"2012","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/22939995","citation_count":56,"is_preprint":false},{"pmid":"10903502","id":"PMC_10903502","title":"Fibrinogen interactions with ICAM-1 (CD54) regulate endothelial cell survival.","date":"2000","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10903502","citation_count":55,"is_preprint":false},{"pmid":"7686194","id":"PMC_7686194","title":"Immune modulation of adhesion molecules ICAM-1 (CD54) and LFA-3 (CD58) in human hepatocytic cell lines.","date":"1993","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/7686194","citation_count":54,"is_preprint":false},{"pmid":"1683677","id":"PMC_1683677","title":"Expression of the leucocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade.","date":"1991","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/1683677","citation_count":54,"is_preprint":false},{"pmid":"18420209","id":"PMC_18420209","title":"ICAM1 and VCAM1 polymorphisms, coronary artery calcium, and circulating levels of soluble ICAM-1: the multi-ethnic study of atherosclerosis (MESA).","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/18420209","citation_count":53,"is_preprint":false},{"pmid":"25786691","id":"PMC_25786691","title":"FOXO1 regulates dendritic cell activity through ICAM-1 and CCR7.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25786691","citation_count":50,"is_preprint":false},{"pmid":"32887724","id":"PMC_32887724","title":"PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32887724","citation_count":48,"is_preprint":false},{"pmid":"33474594","id":"PMC_33474594","title":"Macrophage ICAM-1 functions as a regulator of phagocytosis in LPS induced endotoxemia.","date":"2021","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/33474594","citation_count":48,"is_preprint":false},{"pmid":"8093883","id":"PMC_8093883","title":"De novo expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in pancreas cancer.","date":"1993","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8093883","citation_count":48,"is_preprint":false},{"pmid":"28373581","id":"PMC_28373581","title":"Endothelial MAPKs Direct ICAM-1 Signaling to Divergent Inflammatory Functions.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28373581","citation_count":47,"is_preprint":false},{"pmid":"25654110","id":"PMC_25654110","title":"Regulation of ICAM-1 in cells of the monocyte/macrophage system in microgravity.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25654110","citation_count":45,"is_preprint":false},{"pmid":"14514759","id":"PMC_14514759","title":"Proteolysis of ICAM-1 on human oral epithelial cells by gingipains.","date":"2003","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/14514759","citation_count":45,"is_preprint":false},{"pmid":"1958278","id":"PMC_1958278","title":"T-cell receptors and ICAM-1 expression in renal allografts during rejection.","date":"1991","source":"Transplant international : official journal of the European Society for Organ Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/1958278","citation_count":45,"is_preprint":false},{"pmid":"28042317","id":"PMC_28042317","title":"CD54-NOTCH1 axis controls tumor initiation and cancer stem cell functions in human prostate cancer.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28042317","citation_count":44,"is_preprint":false},{"pmid":"22345292","id":"PMC_22345292","title":"CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22345292","citation_count":43,"is_preprint":false},{"pmid":"10527686","id":"PMC_10527686","title":"Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis.","date":"1999","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/10527686","citation_count":43,"is_preprint":false},{"pmid":"10495789","id":"PMC_10495789","title":"Regulation of RANTES and ICAM-1 expression in murine mesangial cells.","date":"1997","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/10495789","citation_count":42,"is_preprint":false},{"pmid":"23426775","id":"PMC_23426775","title":"Intercellular adhesion molecule-1 (ICAM-1, CD54) is increased in adhesive capsulitis.","date":"2013","source":"The Journal of bone and joint surgery. American volume","url":"https://pubmed.ncbi.nlm.nih.gov/23426775","citation_count":42,"is_preprint":false},{"pmid":"1362919","id":"PMC_1362919","title":"Expression and functional role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on human blood cells.","date":"1992","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/1362919","citation_count":40,"is_preprint":false},{"pmid":"7902828","id":"PMC_7902828","title":"Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy.","date":"1993","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7902828","citation_count":40,"is_preprint":false},{"pmid":"30959276","id":"PMC_30959276","title":"Musashi-1 Enhances Glioblastoma Migration by Promoting ICAM1 Translation.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30959276","citation_count":38,"is_preprint":false},{"pmid":"33785590","id":"PMC_33785590","title":"ICAM-1 orchestrates the abscopal effect of tumor radiotherapy.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33785590","citation_count":38,"is_preprint":false},{"pmid":"1372880","id":"PMC_1372880","title":"Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.","date":"1992","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/1372880","citation_count":37,"is_preprint":false},{"pmid":"1362180","id":"PMC_1362180","title":"Characterization of the murine Icam-1 gene.","date":"1992","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/1362180","citation_count":37,"is_preprint":false},{"pmid":"36921037","id":"PMC_36921037","title":"A YAP/TAZ-CD54 axis is required for CXCR2-CD44- tumor-specific neutrophils to suppress gastric cancer.","date":"2023","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/36921037","citation_count":36,"is_preprint":false},{"pmid":"31585707","id":"PMC_31585707","title":"Human Neutrophils Will Crawl Upstream on ICAM-1 If Mac-1 Is Blocked.","date":"2019","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/31585707","citation_count":35,"is_preprint":false},{"pmid":"33882812","id":"PMC_33882812","title":"Hindering the Synchronization Between miR-486-5p and H19 lncRNA by Hesperetin Halts Breast Cancer Aggressiveness Through Tuning ICAM-1.","date":"2022","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33882812","citation_count":35,"is_preprint":false},{"pmid":"16930678","id":"PMC_16930678","title":"Clonal senescence alters endothelial ICAM-1 function.","date":"2006","source":"Mechanisms of ageing and development","url":"https://pubmed.ncbi.nlm.nih.gov/16930678","citation_count":34,"is_preprint":false},{"pmid":"21391218","id":"PMC_21391218","title":"CCN6 enhances ICAM-1 expression and cell motility in human chondrosarcoma cells.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21391218","citation_count":33,"is_preprint":false},{"pmid":"7657294","id":"PMC_7657294","title":"Differential expression and release of CD54 induced by cytokines.","date":"1995","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/7657294","citation_count":33,"is_preprint":false},{"pmid":"12576228","id":"PMC_12576228","title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies.","date":"2003","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/12576228","citation_count":32,"is_preprint":false},{"pmid":"8774481","id":"PMC_8774481","title":"Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma.","date":"1996","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/8774481","citation_count":31,"is_preprint":false},{"pmid":"18528404","id":"PMC_18528404","title":"Variation in the ICAM1 gene is not associated with severe malaria phenotypes.","date":"2008","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18528404","citation_count":30,"is_preprint":false},{"pmid":"12624779","id":"PMC_12624779","title":"Strong expression of CD40, CD54 and HLA-DR antigen and lack of evidence for direct cellular cytotoxicity are unique immunohistopathological features in alopecia areata.","date":"2002","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/12624779","citation_count":30,"is_preprint":false},{"pmid":"33344137","id":"PMC_33344137","title":"A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33344137","citation_count":30,"is_preprint":false},{"pmid":"21866310","id":"PMC_21866310","title":"Highly osteogenic PDL stem cell clones specifically express elevated levels of ICAM1, ITGB1 and TERT.","date":"2011","source":"Cytotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21866310","citation_count":29,"is_preprint":false},{"pmid":"31491723","id":"PMC_31491723","title":"ICAM-1 in HIV infection and underlying mechanisms.","date":"2019","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/31491723","citation_count":28,"is_preprint":false},{"pmid":"10812972","id":"PMC_10812972","title":"ICAM-1 receptors and cold viruses.","date":"2000","source":"Pharmaceutica acta Helvetiae","url":"https://pubmed.ncbi.nlm.nih.gov/10812972","citation_count":28,"is_preprint":false},{"pmid":"31619256","id":"PMC_31619256","title":"NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31619256","citation_count":28,"is_preprint":false},{"pmid":"39690461","id":"PMC_39690461","title":"Engineered Magneto-Piezoelectric Nanoparticles-Enhanced Scaffolds Disrupt Biofilms and Activate Oxidative Phosphorylation in Icam1+ Macrophages for Infectious Bone Defect Regeneration.","date":"2024","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/39690461","citation_count":27,"is_preprint":false},{"pmid":"36352295","id":"PMC_36352295","title":"Fibrinogen promotes gallbladder cancer cell metastasis and extravasation by inducing ICAM1 expression.","date":"2022","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36352295","citation_count":27,"is_preprint":false},{"pmid":"10029248","id":"PMC_10029248","title":"Altered expression of CD4, CD54, CD62L, and CCR5 in primary lymphocytes productively infected with the human immunodeficiency virus.","date":"1999","source":"AIDS research and human retroviruses","url":"https://pubmed.ncbi.nlm.nih.gov/10029248","citation_count":27,"is_preprint":false},{"pmid":"7540252","id":"PMC_7540252","title":"Increased expression of adhesion molecules (CD54, CD29 and CD44) on fibroblasts infected with cytomegalovirus.","date":"1995","source":"Microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7540252","citation_count":26,"is_preprint":false},{"pmid":"7519509","id":"PMC_7519509","title":"Expression of adhesion molecules CD11/CD18 (Leu-CAMs, beta 2-integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B-chronic lymphocytic leukemia.","date":"1994","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/7519509","citation_count":25,"is_preprint":false},{"pmid":"8620558","id":"PMC_8620558","title":"Selective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides.","date":"1996","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8620558","citation_count":25,"is_preprint":false},{"pmid":"7509669","id":"PMC_7509669","title":"Expression of the Hermes-1 (CD44) and ICAM-1 (CD54) molecule on the surface of thyroid cells from patients with Graves' disease.","date":"1993","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/7509669","citation_count":25,"is_preprint":false},{"pmid":"33947819","id":"PMC_33947819","title":"ICAM-1 induced rearrangements of capsid and genome prime rhinovirus 14 for activation and uncoating.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33947819","citation_count":25,"is_preprint":false},{"pmid":"11222909","id":"PMC_11222909","title":"Production of polyclonal and monoclonal antibodies against CD54 molecules by intrasplenic immunization of plasmid DNA encoding CD54 protein.","date":"2001","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/11222909","citation_count":24,"is_preprint":false},{"pmid":"26666474","id":"PMC_26666474","title":"IL-33 promotes ICAM-1 expression via NF-kB in murine mast cells.","date":"2015","source":"Allergology international : official journal of the Japanese Society of Allergology","url":"https://pubmed.ncbi.nlm.nih.gov/26666474","citation_count":24,"is_preprint":false},{"pmid":"23928509","id":"PMC_23928509","title":"Early cochlear response and ICAM-1 expression to cochlear implantation.","date":"2013","source":"Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology","url":"https://pubmed.ncbi.nlm.nih.gov/23928509","citation_count":24,"is_preprint":false},{"pmid":"10704620","id":"PMC_10704620","title":"ICAM-1 expression by vascular smooth muscle cells is phenotype-dependent.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10704620","citation_count":24,"is_preprint":false},{"pmid":"7693986","id":"PMC_7693986","title":"Increased ICAM-1 expression in aortic disease.","date":"1993","source":"Journal of vascular surgery","url":"https://pubmed.ncbi.nlm.nih.gov/7693986","citation_count":23,"is_preprint":false},{"pmid":"7743678","id":"PMC_7743678","title":"The kinetics of surface expression of CD11/CD18 integrins and CD54 on monocytes and macrophages.","date":"1995","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7743678","citation_count":23,"is_preprint":false},{"pmid":"7843226","id":"PMC_7843226","title":"Co-ligation of ICAM-1 (CD54) and membrane IgM negatively affects B cell receptor signaling.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7843226","citation_count":23,"is_preprint":false},{"pmid":"31100312","id":"PMC_31100312","title":"Unprecedently high targeting specificity toward lung ICAM-1 using 3DNA nanocarriers.","date":"2019","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/31100312","citation_count":21,"is_preprint":false},{"pmid":"8656679","id":"PMC_8656679","title":"The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8656679","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51957,"output_tokens":7342,"usd":0.133,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16537,"output_tokens":6696,"usd":0.125043,"stage2_stop_reason":"end_turn"},"total_usd":0.258043,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"ICAM-1 (CD54) functions as a counter-receptor for Mac-1 (CD11b/CD18) in addition to LFA-1. Purified Mac-1 and ICAM-1 bind each other in reciprocal cell binding assays using transfected cell lines and immunoaffinity-purified proteins; this interaction mediates adhesion between stimulated neutrophils and stimulated endothelial cells.\",\n      \"method\": \"Reciprocal cell binding assays with purified proteins, transfected COS and L cells expressing Mac-1 or ICAM-1, antibody blocking, two-color fluorescence conjugate assays\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reciprocal binding with purified proteins and transfected cells, multiple orthogonal assays (binding, blocking, conjugate), replicated across cell systems\",\n      \"pmids\": [\"1980124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CD43 (sialophorin/leukosialin) binds ICAM-1 (CD54). Daudi cells bind specifically to purified immobilized CD43, and ICAM-1 was identified as a ligand for CD43 on Daudi cells.\",\n      \"method\": \"Purified immobilized CD43 binding assay, identification of ICAM-1 as the Daudi cell surface ligand\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding with purified CD43, single lab, identification of ICAM-1 as counterligand\",\n      \"pmids\": [\"1683685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Clustering of endothelial ICAM-1 triggers a novel clathrin- and caveolin-independent endocytic pathway that requires dynamin-2, actin rearrangements, Src kinase, and Rho kinase (ROCK), and stimulates formation of actin stress fibers. Internalization requires multimeric (not monomeric) antibody conjugates.\",\n      \"method\": \"Uptake of anti-ICAM-1 conjugates by endothelial cells; dominant-negative dynamin-2 constructs; pharmacological inhibitors of clathrin, caveolae, macropinocytosis, Src, and ROCK; colocalization studies; actin staining in HUVEC\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal inhibitors, dominant-negative constructs, colocalization, single rigorous study with multiple mechanistic layers\",\n      \"pmids\": [\"12640043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"p53 activates ICAM-1 transcription via two functional p53-responsive elements located in the introns of the ICAM-1 gene, in an NF-κB-independent manner. DNA damage-induced ICAM-1 expression is abolished by the p53 inhibitor pifithrin-alpha and abrogated in p53-deficient cell lines.\",\n      \"method\": \"p53 inhibitor (pifithrin-alpha), p53-deficient cell lines, mapping of p53-responsive elements in ICAM-1 introns, reporter assays, NF-κB inhibition experiments\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — functional p53 element mapping in ICAM-1 gene, multiple complementary genetic and pharmacological approaches, single lab\",\n      \"pmids\": [\"12660163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Fibrinogen (Fg) binding to ICAM-1 mediates endothelial cell survival through an anti-apoptotic mechanism. Fg:ICAM-1 ligation induces hyperphosphorylation of ERK-1/2 (8-10 fold) in a cytoskeleton-dependent manner, activating the MAP kinase pathway and upregulating survival factor A1; blocking with ICAM-1(8-22) peptide or dominant-negative ERK-1/2 causes apoptosis.\",\n      \"method\": \"Annexin V binding apoptosis assay, ERK-1/2 phosphorylation assays, recognition peptides (Fg-gamma-(117-133) and ICAM-1(8-22)), MEK-1 inhibitor (PD 98059), cytoskeleton disruption (cytochalasin B, nocodazole), dominant-negative ERK-1/2 transfection\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (peptide blocking, dominant-negative, kinase inhibitor, apoptosis assay), single lab\",\n      \"pmids\": [\"10903502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ICAM-1 expression by vascular smooth muscle cells (SMC) is phenotype-dependent: freshly isolated SMC with high myofilament content express little ICAM-1 (non-inducible by IL-1β), whereas phenotypically modulated SMC with low myofilament content constitutively express ICAM-1 and upregulate it further with IL-1β. Signaling involves adenylyl cyclase but not protein kinase C or NF-κB.\",\n      \"method\": \"Immunofluorescence staining, flow cytometry, pharmacological inhibitors of PKC (chelerythrine), PTK (genistein), NF-κB (PDTC), and adenylyl cyclase (forskolin) in primary rat aortic SMC\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — phenotype-dependent expression with multiple pharmacological probes, single lab\",\n      \"pmids\": [\"10704620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Protein kinase C activation (by PMA) induces ICAM-1 expression through a staurosporine-sensitive pathway, whereas IL-1β, TNF-α, and LPS induce ICAM-1 via distinct kinase pathway(s) insensitive to staurosporine. Ionomycin acts synergistically with PMA but not with cytokines or LPS in upregulating ICAM-1.\",\n      \"method\": \"Protein kinase inhibitors (H-7, HA1004, staurosporine), ionomycin treatment, ELISA and immunoprecipitation of biosynthetically labeled ICAM-1 in HUVEC\",\n      \"journal\": \"The American journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — discriminatory pharmacological dissection with multiple inhibitors and activators, single lab\",\n      \"pmids\": [\"1347198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Endothelial ICAM-1 engagement activates ERK, p38, and JNK MAPKs; JNK (and to a lesser degree p38) is the principal MAPK mediating lymphocyte diapedesis across both cerebral and dermal microvascular endothelial cells, whereas ERK is additionally required for TEM across dermal MVECs. JNK drives ICAM-1-induced F-actin rearrangements and phosphorylation of paxillin, which associates with VE-cadherin and promotes its internalization, facilitating lymphocyte TEM. ERK, p38, and JNK also regulate ICAM-1-dependent inflammatory gene expression (TNF-α, CXCL8, CCL3, CCL4, VCAM-1, COX-2).\",\n      \"method\": \"ICAM-1 engagement by lymphocyte adhesion and antibody clustering; MAPK inhibitors; F-actin staining; paxillin phosphorylation/co-immunoprecipitation with VE-cadherin; VE-cadherin internalization assays; CD4+ lymphocyte TEM assays across cerebral and dermal MVECs\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (kinase inhibitors, co-IP, internalization, actin staining, functional TEM assay), single lab, two cell types\",\n      \"pmids\": [\"28373581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Co-ligation of ICAM-1 (CD54) with membrane IgM on B cells inhibits BCR-induced intracellular Ca2+ mobilization (both from intracellular stores and extracellular influx), demonstrating that ICAM-1 is coupled to intracellular signaling pathways and can negatively modulate B cell receptor signaling.\",\n      \"method\": \"Intracellular Ca2+ measurement in Burkitt lymphoma B cells (MTLM4); co-ligation of mIgM and CD54 with limiting anti-IgM concentrations; multiple anti-CD54 mAb tested; Ca2+ measurements in presence and absence of extracellular Ca2+\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — functional Ca2+ signaling assay, multiple antibodies tested, single lab\",\n      \"pmids\": [\"7843226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ICAM-1 (CD54) on target cells provides costimulation for NK cell-mediated cytotoxicity via LFA-1/MAC-1 interactions. In a three-cell experimental system, ICAM-1-transfected cells (but not LFA-3-transfected cells) significantly enhanced NK cell lysis of K562 targets and anti-CD16-coated targets, acting through remote signaling rather than direct adhesion to target.\",\n      \"method\": \"Three-cell experimental system with NK cells, 51Cr-labeled target cells, and ICAM-1-transfected or LFA-3-transfected murine cells as costimulators; cytotoxicity assays\",\n      \"journal\": \"Cellular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — transfected cell system with functional NK cytotoxicity readout, single lab\",\n      \"pmids\": [\"7518755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ICAM-1 downregulation suppresses human breast cancer cell invasion through Matrigel without affecting proliferation or migration. Anti-ICAM-1 antibody blocks invasion of MDA-MB-435 cells dose-dependently, establishing a causal role for ICAM-1 in cancer cell invasion.\",\n      \"method\": \"ICAM-1 siRNA knockdown, anti-ICAM-1 antibody blocking, Matrigel invasion assay, cell proliferation assay in human breast cancer cell lines\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal loss-of-function approaches (siRNA and blocking antibody) with defined invasion phenotype, single lab\",\n      \"pmids\": [\"15774488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structure of rhinovirus 14 complexed with ICAM-1 at 2.4 Å resolution shows that ICAM-1 binding induces conformational changes in the rhinovirus 14 capsid, including translocation of VP4 C-termini, blocking of RNA-VP2 interactions, exposure of positively charged residues, and redistribution of the viral genome — priming the virus for activation and genome release at acidic pH.\",\n      \"method\": \"Cryo-EM structure determination of rhinovirus 14 alone (2.6 Å) and in complex with ICAM-1 (2.4 Å); structural analysis of conformational changes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution cryo-EM structure with mechanistic interpretation of conformational changes, rigorous structural study\",\n      \"pmids\": [\"33947819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Gingipains (cysteine proteinases) from Porphyromonas gingivalis directly cleave ICAM-1 on human oral epithelial cell surfaces in a time- and dose-dependent manner, disrupting ICAM-1-dependent PMN adhesion to epithelial cells, representing a mechanism of immune evasion.\",\n      \"method\": \"Flow cytometry and Western blotting of ICAM-1 on KB and HSC-2 cells; treatment with purified gingipain forms; fixed-cell proteolysis assay; PMN adhesion assay\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct proteolysis on fixed cells confirmed, multiple gingipain forms tested, functional adhesion assay, single lab\",\n      \"pmids\": [\"14514759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Aldosterone promotes endothelial ICAM-1 transcription through the mineralocorticoid receptor (MR). Luciferase reporter assays with deletion constructs of the ICAM-1 promoter in HUVECs identified a region containing an MR-responsive element (MRE) required for MR-dependent ICAM-1 transcriptional regulation. In vivo, ApoE/ICAM-1 double-knockout mice are protected from aldosterone-induced atherosclerotic plaque growth, confirming ICAM-1 as the effector of aldosterone's pro-atherogenic effects.\",\n      \"method\": \"Luciferase reporter assays with ICAM-1 promoter deletion constructs in HUVECs; ApoE-/-/ICAM-1-/- double-knockout mice; aldosterone-treatment atherosclerosis model\",\n      \"journal\": \"International journal of cardiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — promoter deletion/reporter assays define MRE + genetic rescue in double-KO mice, two complementary approaches, single lab\",\n      \"pmids\": [\"28089144\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ICAM-1 is required cell-intrinsically for the development and function of group 2 innate lymphoid cells (ILC2s). ICAM-1-deficient mice have fewer ILC2s in bone marrow and peripheral tissues; CLP transfer and in vitro culture assays confirm cell-intrinsic regulation. ICAM-1 deficiency impairs ILC2 cytokine production in response to IL-33 via ERK signaling-dependent downregulation of GATA3.\",\n      \"method\": \"ICAM-1-deficient mice; CLP transfer assays; in vitro culture; IL-33 challenge; cytokine measurement; ERK signaling analysis; GATA3 protein quantification\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO + cell-intrinsic transfer assays + defined molecular pathway (ERK/GATA3), single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"30049704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXO1 directly binds the ICAM-1 promoter, stimulates ICAM-1 transcriptional activity, and regulates ICAM-1 expression in dendritic cells (DCs). Transfection of ICAM-1-expressing plasmid into FOXO1-deleted DCs rescues impaired bacterial phagocytosis and chemotaxis, placing ICAM-1 as a key downstream effector of FOXO1 in DC function.\",\n      \"method\": \"ChIP showing FOXO1 binding to ICAM-1 promoter; FOXO1 promoter-luciferase reporter assays; lineage-specific FOXO1 knockout (CD11c.Cre+FOXO1L/L mice); rescue with ICAM-1-expressing plasmid; phagocytosis, chemotaxis, and DC homing assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP + reporter assay + genetic KO + functional rescue, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"25786691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Musashi-1 (MSI1) promotes ICAM-1 translation in glioblastoma cells. RNA immunoprecipitation assays demonstrate that MSI1 physically interacts with ICAM-1 mRNA, and MSI1 knockdown suppresses ICAM-1 expression, cell motility, and invasion; overexpression of ICAM-1 reverses these effects.\",\n      \"method\": \"RNA immunoprecipitation (RIP) assay; MSI1 knockdown; ICAM-1 overexpression rescue; cell motility and invasion assays\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RIP demonstrates direct mRNA interaction, rescue experiment confirms ICAM-1 as downstream effector, single lab\",\n      \"pmids\": [\"30959276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CD54 (ICAM-1) mediates cancer stem cell self-renewal and tumorigenesis in prostate cancer through the p38-Notch1 signaling axis. Silencing CD54 reduces tumorigenesis in vitro and in vivo; dissection of downstream signaling identified p38-Notch1 as the principal pathway.\",\n      \"method\": \"CD54 silencing (siRNA/shRNA); patient-derived xenograft model; in vitro self-renewal assays; in vivo xenograft; pathway inhibition/dissection for p38-Notch1\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KD with in vivo confirmation and pathway dissection, single lab\",\n      \"pmids\": [\"28042317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ICAM-1 expression in non-irradiated tumors enhances activation and tumor infiltration of CD8+ T cells, thereby promoting the abscopal effect of radiotherapy. Genetic or pharmacologic upregulation of ICAM-1 markedly increases abscopal responses in animal models.\",\n      \"method\": \"ICAM-1 knockout; intratumoral injection of recombinant adenovirus encoding ICAM-1; TLR7 agonist nanodrug; PET/optical imaging of ICAM-1 expression; flow cytometry of CD8+ T cells; tumor growth measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacologic gain/loss-of-function in vivo, CD8+ T cell mechanistic readout, single lab\",\n      \"pmids\": [\"33785590\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Macrophage ICAM-1 expression, induced by LPS via TLR4-mediated ROS production, is required for LPS-enhanced macrophage phagocytosis. ICAM-1 neutralizing antibody or ICAM-1 siRNA silencing reduces LPS-induced phagocytosis; TLR4 knockout inhibits cytoplasmic and mitochondrial ROS production, which in turn attenuates ICAM-1 expression.\",\n      \"method\": \"ICAM-1 neutralizing antibody; ICAM-1 siRNA; TLR4 knockout mice; flow cytometry; confocal microscopy; ROS measurement; phagocytosis assay\",\n      \"journal\": \"Inflammation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal loss-of-function (antibody + siRNA) + genetic TLR4 KO for upstream pathway, single lab\",\n      \"pmids\": [\"33474594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In senescent endothelial cells, ICAM-1 transitions from directed to random motion within the membrane. Single particle tracking shows 44% reduced ICAM-1 mobility in late-passage cells after PKC stimulation, partly explained by reduced alpha-actinin linking with ICAM-1 and markedly reduced tyrosine phosphorylation of alpha-actinin (required for ICAM-1 clustering) in senescent cells.\",\n      \"method\": \"Single particle tracking; PKC activator (PMA); immunoprecipitation of alpha-actinin with ICAM-1; tyrosine phosphorylation assay; early vs. late passage HPAEC comparison\",\n      \"journal\": \"Mechanisms of ageing and development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — single particle tracking with co-IP and phosphorylation analysis, single lab\",\n      \"pmids\": [\"16930678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"NANOG directly binds to the region upstream of the ICAM-1 gene, and increased NANOG binding is associated with diminished p300 binding at this region, resulting in decreased ICAM-1 expression. This mechanism enables prostate cancer cells to evade NK cell attack during tumorigenesis.\",\n      \"method\": \"RNAseq; ChIPseq of NANOG and p300 at the ICAM-1 upstream region; NANOG overexpression; NK cell cytotoxicity assays; xenograft in SCID mice\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIPseq demonstrates direct NANOG binding + p300 displacement at ICAM-1 locus, functional NK assay, single lab\",\n      \"pmids\": [\"31619256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MicroRNA-222 (miR-222) transported into endothelial cells by endothelial microparticles (EMP) post-transcriptionally downregulates ICAM-1 expression (mRNA and protein), reducing monocyte adhesion in vitro and endothelial ICAM-1 expression in ApoE-/- mice in vivo.\",\n      \"method\": \"Taqman microRNA array; miR-222 transfer via EMP; ICAM-1 mRNA and protein measurement; monocyte adhesion assay; ApoE-/- mouse in vivo model; miR-222 mimic/inhibitor experiments\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — miRNA array + functional miR transfer + in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"26081516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"CD30L and CD40L (but not 4-1BBL) upregulate ICAM-1 (CD54) surface expression and shedding in Hodgkin and Reed-Sternberg (H-RS) cells via transcriptional gene activation, as demonstrated at both mRNA and protein levels. Enhanced surface ICAM-1 is accompanied by increased shedding of an 82 kDa soluble CD54 form.\",\n      \"method\": \"CD30L and CD40L stimulation of H-RS cell lines; ICAM-1 mRNA and protein measurement; soluble CD54 measurement in culture supernatants\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cytokine stimulation assays, mRNA/protein readouts, single lab, no detailed mechanistic dissection\",\n      \"pmids\": [\"8656679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"90% of human rhinovirus (HRV) serotypes use ICAM-1 as a cell-entry receptor. ICAM-1 positions the virus near the membrane and triggers a conformational change in the viral capsid leading to genome delivery across the lipid bilayer. Structural models from crystal structures of HRV and ICAM-1 fragments combined with EM reconstructions of complexes define receptor recognition and uncoating mechanism.\",\n      \"method\": \"Combined crystal structures of HRVs and ICAM-1 fragments with electron microscopy reconstructions of rhinovirus-ICAM-1 complexes\",\n      \"journal\": \"Pharmaceutica acta Helvetiae\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural analysis (crystal + EM), but review/summary paper compiling prior structural work; no new experiment described in abstract\",\n      \"pmids\": [\"10812972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IL-33 induces ICAM-1 expression in murine mast cells via the NF-κB pathway, and this ICAM-1 upregulation increases mast cell adhesion to LFA-1-coated plates. Pre-treatment with an NF-κB inhibitor dramatically reduces IL-33-induced ICAM-1 expression.\",\n      \"method\": \"IL-33 stimulation of bone marrow-derived mast cells (BMMCs); NF-κB inhibitor; ICAM-1 siRNA transfection; cell adhesion assay to LFA-1-coated plate; in vivo IL-33 intradermal injection in mice with ICAM-1 immunohistochemistry\",\n      \"journal\": \"Allergology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — NF-κB inhibitor + siRNA + functional adhesion assay + in vivo confirmation, single lab\",\n      \"pmids\": [\"26666474\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ICAM-1 (CD54) is a transmembrane immunoglobulin superfamily glycoprotein that functions as an adhesion and signaling molecule: it serves as a counter-receptor for leukocyte integrins LFA-1 and Mac-1 (mediating leukocyte firm arrest and transendothelial migration), acts as the entry receptor for ~90% of human rhinovirus serotypes (binding induces conformational changes in the viral capsid that prime genome release), engages fibrinogen to activate ERK-dependent endothelial cell survival signaling, triggers a novel dynamin/actin/ROCK-dependent endocytic pathway upon clustering, activates ERK/p38/JNK MAPKs upon leukocyte engagement to direct both lymphocyte diapedesis (via JNK-paxillin-VE-cadherin) and inflammatory gene expression, is transcriptionally regulated by NF-κB, p53 (via intronic response elements), mineralocorticoid receptor, and FOXO1, and post-transcriptionally regulated by miR-222; ICAM-1 also controls ILC2 development and function via ERK/GATA3 signaling and mediates cancer cell invasion, stem cell self-renewal (via p38-Notch1), and NK cell evasion (through NANOG-mediated transcriptional repression).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ICAM-1 (CD54) is a cell-surface adhesion and signaling receptor that orchestrates leukocyte trafficking, immune cell function, and pathogen entry [#0, #7]. It serves as a counter-receptor for the leukocyte integrins LFA-1 and Mac-1 (CD11b/CD18), mediating firm adhesion between stimulated neutrophils and endothelial cells [#0], and also engages CD43 as an additional counter-ligand [#1]. Beyond passive adhesion, ICAM-1 is a bidirectional signaling molecule: endothelial engagement activates ERK, p38, and JNK MAPKs, with JNK driving F-actin rearrangement and paxillin phosphorylation that promotes VE-cadherin internalization to permit lymphocyte transendothelial migration, while the same MAPKs drive inflammatory gene expression [#7]. Clustering of endothelial ICAM-1 triggers a distinct clathrin- and caveolin-independent endocytic route dependent on dynamin-2, actin, Src, and ROCK [#2], and its membrane mobility and clustering are governed by alpha-actinin linkage and tyrosine phosphorylation [#20]. ICAM-1 also transduces survival signals: fibrinogen binding induces cytoskeleton-dependent ERK-1/2 hyperphosphorylation and anti-apoptotic A1 upregulation in endothelium [#4]. As an entry receptor for ~90% of human rhinovirus serotypes, ICAM-1 binding induces capsid conformational changes—VP4 C-terminus translocation, disruption of RNA-VP2 contacts, and genome redistribution—that prime the virus for uncoating and genome release [#24, #11]. ICAM-1 transcription is controlled by multiple inputs including p53 via intronic response elements [#3], the mineralocorticoid receptor [#13], FOXO1 in dendritic cells [#15], and NF-\\u03baB [#25], and is repressed by NANOG via p300 displacement [#21] and post-transcriptionally by miR-222 [#22] and stabilized translationally by Musashi-1 [#16]. Functionally, ICAM-1 is required cell-intrinsically for ILC2 development through ERK/GATA3 signaling [#14], supports macrophage phagocytosis downstream of TLR4/ROS [#19], and contributes to cancer cell invasion and stem cell self-renewal via p38-Notch1 [#10, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established that ICAM-1 is not solely an LFA-1 ligand but also a counter-receptor for the integrin Mac-1, broadening its role in neutrophil-endothelial adhesion.\",\n      \"evidence\": \"Reciprocal binding with purified Mac-1 and ICAM-1, transfected COS/L cells, antibody blocking, and conjugate assays\",\n      \"pmids\": [\"1980124\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Affinity and stoichiometry of the Mac-1 interaction not quantified\", \"Downstream signaling from Mac-1 engagement not addressed\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Identified CD43 as an additional ICAM-1 counter-ligand, expanding the repertoire of ICAM-1 adhesion partners beyond integrins.\",\n      \"evidence\": \"Purified immobilized CD43 binding assay with Daudi cells\",\n      \"pmids\": [\"1683685\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context of CD43-ICAM-1 binding unclear\", \"No reciprocal validation or structural mapping\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Distinguished signaling routes inducing ICAM-1, showing PKC-dependent induction is mechanistically separate from cytokine/LPS-driven induction.\",\n      \"evidence\": \"Kinase inhibitors and PMA/ionomycin treatment with ELISA/IP in HUVEC\",\n      \"pmids\": [\"1347198\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific cytokine-induced kinases not identified\", \"Transcription factors mediating each route undefined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed ICAM-1 on target cells costimulates NK cytotoxicity through remote signaling rather than direct target adhesion, implicating it in NK effector function.\",\n      \"evidence\": \"Three-cell cytotoxicity system with ICAM-1- vs LFA-3-transfected costimulators\",\n      \"pmids\": [\"7518755\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of 'remote' signaling not defined\", \"Receptor on NK cells transmitting the signal unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated ICAM-1 is coupled to intracellular signaling and can negatively modulate BCR-induced calcium flux in B cells.\",\n      \"evidence\": \"Intracellular Ca2+ measurement with mIgM/CD54 co-ligation in Burkitt lymphoma cells\",\n      \"pmids\": [\"7843226\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling intermediates linking ICAM-1 to Ca2+ suppression unknown\", \"Physiological relevance to B cell biology not established\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed ICAM-1 as a survival receptor, with fibrinogen ligation activating ERK to suppress endothelial apoptosis.\",\n      \"evidence\": \"Apoptosis assays, ERK phosphorylation, recognition peptides, dominant-negative ERK, MEK inhibitor in endothelial cells\",\n      \"pmids\": [\"10903502\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cytoplasmic adaptor coupling ICAM-1 to ERK not identified\", \"In vivo relevance of fibrinogen-ICAM-1 survival signaling untested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed ICAM-1 expression in vascular smooth muscle is phenotype-dependent and uses an adenylyl cyclase route distinct from NF-\\u03baB/PKC.\",\n      \"evidence\": \"Immunofluorescence, flow cytometry, pharmacological inhibitors in primary rat aortic SMC\",\n      \"pmids\": [\"10704620\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factors downstream of adenylyl cyclase not identified\", \"Single-species (rat) primary cells\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined p53 as a direct transcriptional activator of ICAM-1 via intronic response elements, linking DNA damage to adhesion molecule expression independent of NF-\\u03baB.\",\n      \"evidence\": \"p53 inhibitor, p53-null cell lines, intronic element mapping, reporter assays\",\n      \"pmids\": [\"12660163\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological setting of p53-driven ICAM-1 induction unclear\", \"Cofactors at intronic elements not characterized\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovered that ICAM-1 clustering activates a novel dynamin/actin/Src/ROCK-dependent endocytic pathway, defining how engaged ICAM-1 is internalized.\",\n      \"evidence\": \"Anti-ICAM-1 conjugate uptake, dominant-negative dynamin-2, pathway inhibitors, colocalization, actin staining in HUVEC\",\n      \"pmids\": [\"12640043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cargo and fate of internalized ICAM-1 not fully traced\", \"Link between this pathway and leukocyte transmigration not established\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified bacterial proteolysis of ICAM-1 by P. gingivalis gingipains as an immune evasion mechanism that disrupts neutrophil adhesion.\",\n      \"evidence\": \"Flow cytometry/Western of cleaved ICAM-1, fixed-cell proteolysis, PMN adhesion assay\",\n      \"pmids\": [\"14514759\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cleavage sites not mapped\", \"In vivo contribution to periodontal immune evasion untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established a causal role for ICAM-1 in cancer cell invasion independent of proliferation or migration.\",\n      \"evidence\": \"siRNA knockdown and blocking antibody in Matrigel invasion assay in breast cancer cells\",\n      \"pmids\": [\"15774488\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mediators of invasion downstream of ICAM-1 not identified\", \"Limited to single cancer cell line\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Linked ICAM-1 membrane mobility and clustering to alpha-actinin cytoskeletal coupling, which is lost in senescent endothelium.\",\n      \"evidence\": \"Single particle tracking, alpha-actinin co-IP, tyrosine phosphorylation assay in early vs late passage endothelial cells\",\n      \"pmids\": [\"16930678\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinase phosphorylating alpha-actinin not identified\", \"Functional consequence for leukocyte capture in senescence not measured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified FOXO1 as a direct ICAM-1 promoter activator and showed ICAM-1 is the key effector of FOXO1 in dendritic cell phagocytosis and chemotaxis.\",\n      \"evidence\": \"ChIP, reporter assays, lineage-specific FOXO1 knockout, ICAM-1 rescue, DC functional assays\",\n      \"pmids\": [\"25786691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ICAM-1 promotes DC chemotaxis mechanistically unclear\", \"Other FOXO1 targets contributing to phenotype not excluded\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed IL-33 induces mast cell ICAM-1 via NF-\\u03baB to promote LFA-1-dependent adhesion, integrating ICAM-1 into allergic effector responses.\",\n      \"evidence\": \"IL-33 stimulation, NF-\\u03baB inhibitor, ICAM-1 siRNA, adhesion assay, in vivo IL-33 injection\",\n      \"pmids\": [\"26666474\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific NF-\\u03baB subunits at the ICAM-1 promoter not defined\", \"Downstream signaling from mast cell ICAM-1 not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Established post-transcriptional control of ICAM-1 by microparticle-delivered miR-222, modulating endothelial monocyte adhesion in atherosclerosis.\",\n      \"evidence\": \"miRNA array, EMP-mediated miR-222 transfer, mRNA/protein readouts, adhesion assay, ApoE-/- mice\",\n      \"pmids\": [\"26081516\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ICAM-1 3'UTR target site not mapped\", \"Other miR-222 targets contributing in vivo not excluded\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated that endothelial ICAM-1 engagement signals through ERK/p38/JNK MAPKs, with JNK driving paxillin-dependent VE-cadherin internalization to enable lymphocyte transendothelial migration and inflammatory gene expression.\",\n      \"evidence\": \"Antibody clustering/adhesion, MAPK inhibitors, co-IP of paxillin with VE-cadherin, internalization and TEM assays across two endothelial types\",\n      \"pmids\": [\"28373581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrate linking ICAM-1 to JNK not defined\", \"How JNK selectively phosphorylates paxillin not resolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Implicated ICAM-1 in cancer stem cell self-renewal and tumorigenesis through the p38-Notch1 axis in prostate cancer.\",\n      \"evidence\": \"CD54 silencing, PDX and xenograft models, self-renewal assays, p38-Notch1 pathway dissection\",\n      \"pmids\": [\"28042317\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ICAM-1 activates p38 in cancer stem cells unclear\", \"Receptor partner triggering this axis not identified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified the mineralocorticoid receptor as a direct transcriptional driver of endothelial ICAM-1 and showed ICAM-1 is the effector of aldosterone's pro-atherogenic effects.\",\n      \"evidence\": \"Promoter deletion/reporter assays defining an MRE, ApoE-/-/ICAM-1-/- double-knockout aldosterone atherosclerosis model\",\n      \"pmids\": [\"28089144\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MR cofactors at the ICAM-1 promoter not characterized\", \"Cell types beyond endothelium not examined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed a cell-intrinsic requirement for ICAM-1 in ILC2 development and IL-33-driven cytokine production via ERK-dependent maintenance of GATA3.\",\n      \"evidence\": \"ICAM-1-deficient mice, CLP transfer, in vitro culture, IL-33 challenge, ERK/GATA3 analysis\",\n      \"pmids\": [\"30049704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ICAM-1 cell-intrinsically activates ERK in ILC2s unknown\", \"Ligand engaging ICAM-1 in this context not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed Musashi-1 binds ICAM-1 mRNA and promotes its translation to drive glioblastoma motility and invasion, defining a translational layer of ICAM-1 control.\",\n      \"evidence\": \"RNA immunoprecipitation, MSI1 knockdown, ICAM-1 overexpression rescue, motility/invasion assays\",\n      \"pmids\": [\"30959276\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MSI1 binding site on ICAM-1 mRNA not mapped\", \"Whether translation enhancement requires other RBPs unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established that NANOG directly represses ICAM-1 by displacing p300 at the locus, enabling prostate cancer NK cell immune evasion.\",\n      \"evidence\": \"ChIPseq of NANOG and p300, NANOG overexpression, NK cytotoxicity, SCID xenograft\",\n      \"pmids\": [\"31619256\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of p300 displacement by NANOG unclear\", \"Other repressive cofactors not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided high-resolution structural mechanism showing ICAM-1 binding to rhinovirus 14 induces capsid conformational changes that prime genome release.\",\n      \"evidence\": \"Cryo-EM of rhinovirus 14 alone and complexed with ICAM-1 at 2.4 \\u00c5\",\n      \"pmids\": [\"33947819\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence of events between binding and uncoating at acidic pH not temporally resolved\", \"Membrane penetration step not visualized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed macrophage ICAM-1, induced via TLR4-mediated ROS, is required for LPS-enhanced phagocytosis, linking innate sensing to ICAM-1 effector function.\",\n      \"evidence\": \"ICAM-1 neutralizing antibody, siRNA, TLR4-KO mice, ROS measurement, phagocytosis assay\",\n      \"pmids\": [\"33474594\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ICAM-1 promotes phagocytic uptake mechanistically unclear\", \"Phagocytic ligand engaging ICAM-1 not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated that ICAM-1 in non-irradiated tumors enhances CD8+ T cell activation and infiltration to promote the abscopal effect of radiotherapy.\",\n      \"evidence\": \"ICAM-1 knockout, adenoviral ICAM-1, TLR7 agonist nanodrug, imaging, CD8+ T cell flow cytometry, tumor growth\",\n      \"pmids\": [\"33785590\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which tumor ICAM-1 enhances CD8+ T cell activation unresolved\", \"Translatability to clinical radiotherapy untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the ICAM-1 cytoplasmic tail mechanistically couples surface engagement to the diverse MAPK, survival, and lineage-specific transcriptional programs across cell types remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model of cytoplasmic adaptor recruitment\", \"Cell-type specificity of ICAM-1 outside-in signaling not explained\", \"Structural basis of integrin (LFA-1/Mac-1) engagement not resolved in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [24, 11]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [7, 4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 7, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 4]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [24, 11]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 13, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ITGAM\", \"ITGB2\", \"ITGAL\", \"CD43\", \"FGA\", \"VE-cadherin\", \"ACTN1\", \"MSI1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}